CYP2D6的影响同工酶在文拉法辛对重度抑郁症患者:临床和经济后果。

文章的细节

引用

复制到剪贴板

Sicras-Mainar, Guijarro P, B,舰队Blanca-Tamayo M, Navarro-Artieda R

CYP2D6的影响同工酶在文拉法辛对重度抑郁症患者:临床和经济后果。

《公共科学图书馆•综合》。2014年11月4日;9 (11):e90453。doi: 10.1371 / journal.pone.0090453。eCollection 2014。

PubMed ID

25369508 (在PubMed

]

文摘

背景:抗抑郁药物的主要药物治疗持续缓解症状。然而,临床结果并不令人鼓舞。这种缺乏反应可能是由于其他原因,因素改变抗抑郁药物的代谢。摘要目的:评价的影响伴随管理功效CYP2D6抑制剂或基质,患者的耐受性和成本文拉法辛重度抑郁症的临床实践。方法:我们设计了一个观察研究使用门诊病人的医疗记录。主题> / = 18岁期间开始文拉法辛2008 - 2010都包括在内。三个学习小组认为:没有组合(参考),venlafaxine-substrate, venlafaxine-inhibitor。随访期为12个月。主要变量:人口数据、发病率、缓解(汉密尔顿< 7),对治疗的反应,不良事件和成本。统计分析包括逻辑回归模型和ANCOVA, p值< 0.05被认为是重要的。 RESULTS: A total of 1,115 subjects were recruited. The mean age was 61.7 years and 75.1% were female. Approximately 33.3% (95% CI: 30.5 to 36.1) were receiving some kind of drug combination (venlafaxine-substrate: 23.0%, and venlafaxine-inhibitor: 10.3%). Compared with the venlafaxine-substrate and venlafaxine-inhibitor groups, patients not taking concomitant drugs had a better response to therapy (49.1% vs. 39.9% and 34.3%, p<0.01), greater remission of symptoms (59.9% vs. 50.2% and 43.8%, p<0.001), fewer adverse events (1.9% vs. 7.0% and 6.1%, p<0.05) and a lower mean adjusted cost (euro2,881.7 vs. euro4,963.3 and euro7,389.1, p<0.001), respectively. All cost components showed these differences. CONCLUSIONS: The patients treated with venlafaxine alone showed a better response to anti-depressant treatment, greater remission of symptoms, a lower incidence of adverse events and lower healthcare costs.

DrugBank数据引用了这篇文章

药物酶

药物	酶	类	生物	药理作用	行动
阿普洛尔	细胞色素P450 2 d6	蛋白质	人类	未知的	底物	细节
Methotrimeprazine	细胞色素P450 2 d6	蛋白质	人类	未知的	底物 抑制剂	细节